University of California San Diego Medical Center
Welcome,         Profile    Billing    Logout  
 20 Trials 
38 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Barshop, Bruce
NCT03897361: Stem Cell Gene Therapy for Cystinosis

Active, not recruiting
1/2
6
US
CTNS-RD-04 or CTNS-RD-04-LB (where the suffix "-LB" stands for LentiBOOST)
University of California, San Diego, California Institute for Regenerative Medicine (CIRM), Cystinosis Research Foundation
Lysosomal Storage Diseases, Cystinosis
11/24
11/24
Haas, Richard H
STRIDE, NCT04535609 / 2020-002855-40: An Efficacy and Safety Study of 24 Week Treatment With Mavodelpar (REN001) in Primary Mitochondrial Myopathy Patients

Completed
2
213
Europe, Canada, US, RoW
Mavodelpar, REN001, Placebo
Reneo Pharma Ltd
Primary Mitochondrial Myopathy
09/23
10/23
NEOLEV3, NCT05610085: A Dose Escalation Study of Levetiracetam in the Treatment of Neonatal Seizures

Recruiting
2
133
US, RoW
Levetiracetam Injection, Phenobarbital Sodium Injection
University of California, San Diego, University of Minnesota, Rady Children's Hospital, San Diego, Auckland City Hospital, University of Auckland, New Zealand, Middlemore Hospital, New Zealand
Neonatal Seizure, Neonatal Encephalopathy, Hypoxic-Ischemic Encephalopathy, Seizure Newborn
07/27
12/27
REVEAL, NCT05606614: Safety and Efficacy of TSHA-102 in Adolescent and Adult Females with Rett Syndrome ( Adult Study)

Recruiting
1/2
18
Canada, US
TSHA-102
Taysha Gene Therapies, Inc.
Rett Syndrome
01/25
01/32
NCT06152237: Safety and Efficacy of TSHA-102 in Pediatric Females with Rett Syndrome (REVEAL Pediatric Study)

Recruiting
1/2
20
Europe, Canada, US
TSHA-102
Taysha Gene Therapies, Inc.
Rett Syndrome
11/28
11/31
NAMDC, NCT01694940: North American Mitochondrial Disease Consortium Patient Registry and Biorepository

Recruiting
N/A
1000
Canada, US
Columbia University, National Institute of Neurological Disorders and Stroke (NINDS)
Mitochondrial Disorders, Mitochondrial Genetic Disorders, Mitochondrial Diseases, Disorder of Mitochondrial Respiratory Chain Complexes, Deletion and Duplication of Mitochondrial DNA
12/25
12/25
Feifel, David
uAspire, NCT06308653: Psilocybin for Major Depressive Disorder (MDD)

Recruiting
3
240
US
Psilocybin 25 mg, Psilocybine, Psilocibin, Indocybin, Inactive Placebo, Microcrystalline Cellulose (MCC), Placebo, Psilocybin 5 mg, Psilocybine, Psilocibin, Indocybin, Active Comparator, Psychosocial Support
Usona Institute, Worldwide Clinical Trials
Depressive Disorder, Major
04/25
04/26
NCT05624268: Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD

Recruiting
3
255
US
Psilocybin, COMP360
COMPASS Pathways
Treatment Resistant Depression
02/25
02/26
NCT05733546: A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder

Recruiting
2
102
US
Psilocybin, COMP360
COMPASS Pathways
Major Depressive Disorder
10/24
11/24
NCT04279522: The MOOD Study - External Combined Occipital and Trigeminal Nerve Stimulation (eCOT-NS) for the Treatment of Major Depressive Disorder (MDD)

Completed
N/A
126
US, RoW
Relivion®DP- Active, Relivion®DP- Sham
Neurolief Ltd.
MDD
06/24
06/24
McHale, Michael T
OnPrime, NCT05281471: Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (, GOG-3076)

Recruiting
3
186
US
olvimulogene nanivacirepvec, GL-ONC1 and GLV-1h68, Platinum chemotherapy: carboplatin (preferred) or cisplatin, Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin, Bevacizumab (or biosimilar)
Genelux Corporation, GOG Foundation
Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, High-grade Serous Ovarian Cancer, Endometrioid Ovarian Cancer, Ovarian Clear Cell Carcinoma
08/25
10/26
HOTT, NCT05659381: Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer

Recruiting
3
230
US
Cisplatin, Platinol AQ, No treatment
GOG Foundation, GlaxoSmithKline
Stage III Ovarian Cancer, Stage IV Ovarian Cancer, Stage III Primary Peritoneal Cancer, Stage IV Primary Peritoneal Cancer, Stage III Fallopian Tube Cancer, Stage IV Fallopian Tube Cancer
08/29
08/34
ROCKIF, NCT03287271: Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK

Recruiting
1/2
90
US
VS-6063, defactinib, Paclitaxel, Taxol, Carboplatin, Paraplatin
Michael McHale, Verastem, Inc., Nine Girls Ask
Ovarian Cancer
04/25
04/26
OVATION 2, NCT03393884: Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer

Checkmark Presentation of OVATION 2 data in advanced ovarian cancer
Mar 2021 - Mar 2021: Presentation of OVATION 2 data in advanced ovarian cancer
Active, not recruiting
1/2
130
Canada, US
IMNN-001, Carboplatin, Paclitaxel
Imunon
Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
07/24
11/25
GARNET, NCT02715284: Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors

Checkmark MFDS approved in Korea in adult patients with recurrent or advanced dMMR/MSI-H 2L endometrial cancer
Dec 2022 - Dec 2022: MFDS approved in Korea in adult patients with recurrent or advanced dMMR/MSI-H 2L endometrial cancer
Checkmark Result from GARNET trial for dMMR endometrial cancer and other solid tumors at ESMO 2022
Sep 2022 - Sep 2022: Result from GARNET trial for dMMR endometrial cancer and other solid tumors at ESMO 2022
Checkmark Approved for recurrent or advanced endometrial cancer
More
Recruiting
1
740
Europe, Canada, US, RoW
Dostarlimab
Tesaro, Inc.
Neoplasms
05/26
10/27
Narayan, Sanjiv M
NCT02169037: Substrate Versus Trigger Ablation for Paroxysmal Atrial Fibrillation

Recruiting
N/A
120
US
FIRM Ablation, Conventional AF ablation with PVI
University of California, San Diego, National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI)
Atrial Fibrillation
07/22
07/22
RECONFIRM, NCT02456233: Evaluation of Conventional Ablation With or Without Focal Impulse and Rotor Modulation to Eliminate Human AF

Recruiting
N/A
120
US
Conventional AF Ablation with PVI, FIRM-guided ablation plus PVI
Stanford University
Atrial Fibrillation
03/25
12/25
COMPARE_AF, NCT02997254: COMParison of Algorithms for Rotational Evaluation in Atrial Fibrillation

Recruiting
N/A
200
US
Stanford University
Atrial Fibrillation, Abnormal Heart Rhythms
11/25
11/26
NCT05371405: Machine Learning in Atrial Fibrillation

Recruiting
N/A
120
US
Stanford University
Atrial Fibrillation, Arrhythmias, Cardiac
12/25
12/26
NCT05366361: The Dynamics of Human Atrial Fibrillation

Recruiting
N/A
200
US
Stanford University
Atrial Fibrillation, Arrhythmias, Cardiac
12/25
12/26
Hoenigl, Martin
FORMULA-OLS, NCT03583164 / 2017-001290-17: Evaluate F901318 (Olorofim) Treatment of Invasive Fungal Infections in Participants Lacking Treatment Options

Completed
2
203
Europe, US, RoW
Olorofim, F901318
F2G Biotech GmbH, Iqvia Pty Ltd
Invasive Fungal Infections
02/23
02/23
Greenberg, Barry
NCT06092034: A Gene Therapy Study of RP-A501 in Male Patients With Danon Disease

Active, not recruiting
2
12
Europe, US
RP-A501
Rocket Pharmaceuticals Inc.
Danon Disease
09/25
09/29
REST, NCT05282550: Targeting Cognition in Early Alzheimer's Disease by Improving Sleep With Trazodone

Recruiting
2
100
US
Trazodone, Desyrel, Placebo
Johns Hopkins University, National Institute on Aging (NIA)
AMCI - Amnestic Mild Cognitive Impairment, Sleep Disturbance
07/27
06/28
NCT03882437: Gene Therapy for Male Patients With Danon Disease (DD) Using RP-A501; AAV9.LAMP2B

Active, not recruiting
1
7
US
RP-A501
Rocket Pharmaceuticals Inc.
Danon Disease
03/25
03/25
NCT05885412: A Phase 1, Dose Escalation Trial of RP-A601 in Subjects With PKP2 Variant-Mediated Arrhythmogenic Cardiomyopathy (PKP2-ACM)

Recruiting
1
9
US
RP-A601
Rocket Pharmaceuticals Inc.
PKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM)
09/25
09/26
VanMeter, Susan
NCT03845712: An Open-Label Study of Continuation Treatment With Combination Pyrimidine Nucleosides in Patients With TK2 Deficiency

Active, not recruiting
2
47
Europe, US, RoW
doxecitine and doxribtimine, MT1621, GMP grade dC/dT (deoxycytidine and deoxythymidine)
UCB BIOSCIENCES, Inc., Zogenix, Inc.
Thymidine Kinase 2 Deficiency
06/25
06/25
Eskander, Ramez
KEYNOTE-868, NCT03914612: Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

Checkmark PFS results in combination with chemotherapy from NRG-GY018 trial for the treatment of 1L advanced or recurrent endometrial carcinoma.
Feb 2023 - Feb 2023: PFS results in combination with chemotherapy from NRG-GY018 trial for the treatment of 1L advanced or recurrent endometrial carcinoma.
Active, not recruiting
3
759
Canada, Japan, US, RoW
Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Placebo Administration, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
National Cancer Institute (NCI), Canadian Cancer Trials Group, NRG Oncology
Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Recurrent Endometrial Adenocarcinoma, Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma, Recurrent Endometrial Dedifferentiated Carcinoma, Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Endometrial Mixed Cell Adenocarcinoma, Recurrent Endometrial Serous Adenocarcinoma, Recurrent Endometrial Undifferentiated Carcinoma, Stage III Uterine Corpus Cancer AJCC v8, Stage IV Uterine Corpus Cancer AJCC v8
12/22
05/24
OnPrime, NCT05281471: Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (, GOG-3076)

Recruiting
3
186
US
olvimulogene nanivacirepvec, GL-ONC1 and GLV-1h68, Platinum chemotherapy: carboplatin (preferred) or cisplatin, Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin, Bevacizumab (or biosimilar)
Genelux Corporation, GOG Foundation
Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, High-grade Serous Ovarian Cancer, Endometrioid Ovarian Cancer, Ovarian Clear Cell Carcinoma
08/25
10/26
FLORA-4, NCT04498117 / 2020-002270-26: Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

Active, not recruiting
3
615
Europe, Canada, US, RoW
Oregovomab, MAb-B43.13, Paclitaxel, Taxol, Carboplatin, Paraplatin, Placebo
CanariaBio Inc., Gynecologic Oncology Group, Iqvia Pty Ltd
Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer, Ovarian Serous Adenocarcinoma, Fallopian Tube Neoplasms, Fallopian Tube Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Peritoneal Cancer, Peritoneal Carcinoma, Peritoneal Neoplasms
09/25
08/27
GLORIOSA, NCT05445778: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer

Recruiting
3
418
Europe, Canada, US, RoW
Mirvetuximab soravtansine plus Bevacizumab, MIRV, Bevacizumab
AbbVie, GOG Foundation
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
03/27
04/29
NRG-GY014, NCT03348631: Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer

Active, not recruiting
2
62
US
Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Tazemetostat, E7438, EPZ-6438, EPZ6438
National Cancer Institute (NCI), NRG Oncology
Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Uterine Corpus Cancer
04/23
09/24
NCT05456685: Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

Checkmark Data from trial in combination with carboplatin for platinum-sensitive epithelial ovarian cancer at IGCS 2022
Sep 2022 - Oct 2022: Data from trial in combination with carboplatin for platinum-sensitive epithelial ovarian cancer at IGCS 2022
Active, not recruiting
2
125
Europe, Canada, US, RoW
Mirvetuximab soravtansine, MIRV, IGN853, Carboplatin
AbbVie
High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
05/26
05/26
DENALI, NCT05128825: A Study of ZN-c3 in Subjects With High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Active, not recruiting
2
102
Europe, US, RoW
ZN-c3, azenosertib
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
04/25
10/25
SURPASS-3, NCT05601752 / 2022-003176-16: ADP-A2M4CD8 Monotherapy and in Combination with Nivolumab in HLA-A2+ Subjects with MAGE-A4 Positive Ovarian Cancer

Active, not recruiting
2
66
Europe, Canada, US
Autologous genetically modified ADP-A2M4CD8 cells, Autologous genetically modified ADP-A2M4CD8 cells in combination with Nivolumab
Adaptimmune, GOG Foundation
Ovarian Cancer
08/26
08/26
ACR-368-201, NCT05548296: A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma

Recruiting
1/2
390
US
ACR-368, prexasertib, Gemcitabine, OncoSignature
Acrivon Therapeutics, GOG Foundation
Platinum-resistant Ovarian Cancer, Endometrial Adenocarcinoma, Urothelial Carcinoma
07/26
12/27
ROCC, NCT04831580: A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer

Recruiting
N/A
840
Canada, US
da Vinci, open surgery
GOG Foundation, Intuitive Foundation
Cervical Cancer
08/28
08/29
Previte, Rosemarie
ALSpire, NCT04494256 / 2020-000207-36: A Study to Assess the Safety, Tolerability, and Effect on Disease Progression of BIIB105 in Participants With Amyotrophic Lateral Sclerosis (ALS) and Participants With the ALS Ataxin-2 (ATXN2) Genetic Mutation

Terminated
1/2
99
Europe, Canada, US
BIIB105, Placebo
Biogen, Biogen Idec Research Limited
Amyotrophic Lateral Sclerosis
08/24
08/24
Kodiyanplakkal, Rosypriya
NCT03808922 / 2018-004318-16: Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study

Recruiting
3
274
Europe, US, RoW
DAS181, Placebo, DAS181 COVID-19, DAS181 OL
Ansun Biopharma, Inc.
Lower Respiratory Tract Infection, Parainfluenza, Immunocompromised, COVID-19
08/25
08/25
Hammack, Margo
No trials found

Download Options